Nischal Koirala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nischal Koirala has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Gordon McLennan
Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
6 shared publications - Jennifer Carlson Aske
Translational Oncology Laboratory, Avera Cancer Institute, Sioux Falls, SD 57108, USA
3 shared publications - Nandini Dey
Translational Oncology Laboratory, Avera Cancer Institute, Sioux Falls, SD 57108, USA
3 shared publications - Luis Rojas Espaillat
Department of Gynecologic Oncology, Avera Cancer Institute, Sioux Falls, SD 57108, USA
2 shared publications Pradip De
Avera Cancer Institute, Sioux Falls, SD
2 shared publications- Xiaoqian Lin
Avera Cancer Institute, Sioux Falls, SD
2 shared publications
Latest Publications
- Open Access
Factors Associated with Total Laryngectomy Utilization in Patients with cT4a Laryngeal Cancer
Background: Despite recommendations for upfront total laryngectomy (TL), many patients with cT4a laryngeal cancer (LC) instead undergo definitive chemoradiation, which is associated with inferior survival. Sociodemographic and oncologic characteristics associated with TL utilization in this population are understudied. Methods: This retrospective cohort study utilized hospital registry data from the National Cancer Database to analyze patients diagnosed with cT4a LC from 2004 to 2017. Patients were stratified by receipt of TL, and patient and facility characteristics were compared between the two groups. Logistic regression analyses and Cox proportional hazards methodology were performed to determine variables associated with receipt of TL and with overall survival (OS), respectively. OS was estimated using the Kaplan–Meier method and compared between treatment groups using log-rank testing. TL usage over time was assessed. Results: There were 11,149 patients identified. TL utilization increased from 36% in 2004 to 55% in 2017. Treatment at an academic/research program (OR 3.06) or integrated network cancer program (OR 1.50), male sex (OR 1.19), and Medicaid insurance (OR 1.31) were associated with increased likelihood of undergoing TL on multivariate analysis (MVA), whereas age > 61 (OR 0.81), Charlson–Deyo comorbidity score ≥ 3 (OR 0.74), and clinically positive regional nodes (OR 0.78 [cN1], OR 0.67 [cN2], OR 0.21 [cN3]) were associated with decreased likelihood. Those undergoing TL with post-operative radiotherapy (+/− chemotherapy) had better survival than those receiving chemoradiation (median OS 121 vs. 97 months; p = 0.003), and TL + PORT was associated with lower risk of death compared to chemoradiation on MVA (HR 0.72; p = 0.024). Conclusions: Usage of TL for cT4a LC is increasing over time but remains below 60%. Patients seeking care at academic/research centers are significantly more likely to undergo TL, highlighting the importance of decreasing barriers to accessing these centers. Increased focus should be placed on understanding and addressing the additional patient-, physician-, and system-level factors that lead to decreased utilization of surgery.
Open AccessFactors Associated with Total Laryngectomy Utilization in Patients with cT4a Laryngeal Cancer
Background: Despite recommendations for upfront total laryngectomy (TL), many patients with cT4a laryngeal cancer (LC) instead undergo definitive chemoradiation, which is associated with inferior survival. Sociodemographic and oncologic characteristics associated with TL utilization in this population are understudied. Methods: This retrospective cohort study utilized hospital registry data from the National Cancer Database to analyze patients diagnosed with cT4a LC from 2004 to 2017. Patients were stratified by receipt of TL, and patient and facility characteristics were compared between the two groups. Logistic regression analyses and Cox proportional hazards methodology were performed to determine variables associated with receipt of TL and with overall survival (OS), respectively. OS was estimated using the Kaplan–Meier method and compared between treatment groups using log-rank testing. TL usage over time was assessed. Results: There were 11,149 patients identified. TL utilization increased from 36% in 2004 to 55% in 2017. Treatment at an academic/research program (OR 3.06) or integrated network cancer program (OR 1.50), male sex (OR 1.19), and Medicaid insurance (OR 1.31) were associated with increased likelihood of undergoing TL on multivariate analysis (MVA), whereas age > 61 (OR 0.81), Charlson–Deyo comorbidity score ≥ 3 (OR 0.74), and clinically positive regional nodes (OR 0.78 [cN1], OR 0.67 [cN2], OR 0.21 [cN3]) were associated with decreased likelihood. Those undergoing TL with post-operative radiotherapy (+/− chemotherapy) had better survival than those receiving chemoradiation (median OS 121 vs. 97 months; p = 0.003), and TL + PORT was associated with lower risk of death compared to chemoradiation on MVA (HR 0.72; p = 0.024). Conclusions: Usage of TL for cT4a LC is increasing over time but remains below 60%. Patients seeking care at academic/research centers are significantly more likely to undergo TL, highlighting the importance of decreasing barriers to accessing these centers. Increased focus should be placed on understanding and addressing the additional patient-, physician-, and system-level factors that lead to decreased utilization of surgery.
- Open Access
- 4 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (13) , 11079
Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers
The bipartite landscape of tumor cells and stromal cells determines a tumor’s response to treatment during disease management. In endometrial cancers (ECs), the mechanistic contribution of PD-L1/L2 and PD-1 signaling of the host’s tumor microenvironment (TME) (CAF and immune cells) in the context of the tumor cells is elusive. To understand the tumor–stroma-immune crosstalk, we studied the compartmental pattern of PD-L1/L2 and PD-1 expression in EC tissues and their matched CAFs. Over 116 surgically resected tumors (T) and the tumor-adjacent normal tissues (N) were obtained from consented unselected consecutive patients. IHC was performed in T, N-epi-thelium, and the stromal mesenchymal environment (SME; mesenchyme) in the T and N tissues. The staining intensity and distribution patterns of PD-L1/L2 and PD-1 in the FFPE sections of T and N were evaluated by a pathologist using a standard scoring system of TPS and CPS. We tested the PD-L1/L2 and PD-1 immune landscape of tumor-TME pair and normal epithelial-stromal mesenchyme pairs from patients with different grades of disease vis-à-vis their CAF PD-L1 levels. We used qRT-PCR to determine the expressions of mRNAs, while the flow cytometry and ICC determined the level of expression of proteins. We observed higher levels of PD-L1 mRNA and protein expression in primary CAFs from the resected tumor tissue compared to the tumor-adjacent normal tissues. We also determined the expression of patients’ soluble PD-L1/L2 as peripheral readouts of PD-L1/L2 and PD-1. As we evaluated the results in the context of their pathological parameters, such as grades, stages, lymphovascular invasion, percentage of myometrial invasion, and dMMR in patients, the dominance of PD-L1 expression in TME was positively correlated to the higher pathological grades of tumors, and its relationship with the dMMR. Since the neutralization of CD8-positive cytotoxic T-cells is PD-L1-dependent, our data indicate that irrespective of the PD-L1 positivity of tumor cells, the PD-L1-positive CAFs can play a critical role in bringing out an additional load of PD-L1 for an effective engagement of PD-1 within a tumor mass.
- 4 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (13) , 11079
Open AccessTumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers
The bipartite landscape of tumor cells and stromal cells determines a tumor’s response to treatment during disease management. In endometrial cancers (ECs), the mechanistic contribution of PD-L1/L2 and PD-1 signaling of the host’s tumor microenvironment (TME) (CAF and immune cells) in the context of the tumor cells is elusive. To understand the tumor–stroma-immune crosstalk, we studied the compartmental pattern of PD-L1/L2 and PD-1 expression in EC tissues and their matched CAFs. Over 116 surgically resected tumors (T) and the tumor-adjacent normal tissues (N) were obtained from consented unselected consecutive patients. IHC was performed in T, N-epi-thelium, and the stromal mesenchymal environment (SME; mesenchyme) in the T and N tissues. The staining intensity and distribution patterns of PD-L1/L2 and PD-1 in the FFPE sections of T and N were evaluated by a pathologist using a standard scoring system of TPS and CPS. We tested the PD-L1/L2 and PD-1 immune landscape of tumor-TME pair and normal epithelial-stromal mesenchyme pairs from patients with different grades of disease vis-à-vis their CAF PD-L1 levels. We used qRT-PCR to determine the expressions of mRNAs, while the flow cytometry and ICC determined the level of expression of proteins. We observed higher levels of PD-L1 mRNA and protein expression in primary CAFs from the resected tumor tissue compared to the tumor-adjacent normal tissues. We also determined the expression of patients’ soluble PD-L1/L2 as peripheral readouts of PD-L1/L2 and PD-1. As we evaluated the results in the context of their pathological parameters, such as grades, stages, lymphovascular invasion, percentage of myometrial invasion, and dMMR in patients, the dominance of PD-L1 expression in TME was positively correlated to the higher pathological grades of tumors, and its relationship with the dMMR. Since the neutralization of CD8-positive cytotoxic T-cells is PD-L1-dependent, our data indicate that irrespective of the PD-L1 positivity of tumor cells, the PD-L1-positive CAFs can play a critical role in bringing out an additional load of PD-L1 for an effective engagement of PD-1 within a tumor mass.
- Open Access
- 22 September 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5572
Percutaneous-Reinforced Osteoplasty: A Review of Emerging Treatment Strategies for Bone Interventions
Percutaneous-reinforced osteoplasty is currently being investigated as a possible therapeutic procedure for fracture stabilization in high-risk patients, primarily in patients with bone metastases or osteoporosis. For these patients, a percutaneous approach, if structurally sound, can provide a viable method for treating bone fractures without the physiologic stress of anesthesia and open surgery. However, the low strength of fixation is a common limitation that requires further refinement in scaffold design and selection of materials, and may potentially benefit from tissue-engineering-based regenerative approaches. Scaffolds that have tissue regenerative properties and low inflammatory response promote rapid healing at the fracture site and are ideal for percutaneous applications. On the other hand, preclinical mechanical tests of fracture-repaired specimens provide key information on restoration strength and long-term stability and enable further design optimization. This review presents an overview of percutaneous-reinforced osteoplasty, emerging treatment strategies for bone repair, and basic concepts of in vitro mechanical characterization.
- 22 September 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5572
Open AccessPercutaneous-Reinforced Osteoplasty: A Review of Emerging Treatment Strategies for Bone Interventions
Percutaneous-reinforced osteoplasty is currently being investigated as a possible therapeutic procedure for fracture stabilization in high-risk patients, primarily in patients with bone metastases or osteoporosis. For these patients, a percutaneous approach, if structurally sound, can provide a viable method for treating bone fractures without the physiologic stress of anesthesia and open surgery. However, the low strength of fixation is a common limitation that requires further refinement in scaffold design and selection of materials, and may potentially benefit from tissue-engineering-based regenerative approaches. Scaffolds that have tissue regenerative properties and low inflammatory response promote rapid healing at the fracture site and are ideal for percutaneous applications. On the other hand, preclinical mechanical tests of fracture-repaired specimens provide key information on restoration strength and long-term stability and enable further design optimization. This review presents an overview of percutaneous-reinforced osteoplasty, emerging treatment strategies for bone repair, and basic concepts of in vitro mechanical characterization.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 1775
Abstract 1775: Scope of cell cycle inhibition in HER2+ breast cancer
Background: Proliferative signaling of the HER2- and ER-pathways converge and propagate via cyclin D and CDK4/6, leading to uncontrolled cell cycle progression and resistance to anti- HER2- and ER-targeted therapies. Purpose: We hypothesize that co-targeting HER2 and CDK4/6 will counter the uncontrolled cell cycle progression, initiate cell cycle arrest, and induce apoptosis in Rb-proficient HER2-amplified breast cancer (BC) cells. Methods: HER2+ BC cell lines (Rb-WT): BT474 (HR-positive), SKBR3 (HR-negative), and MDA-MB453 (HR-negative, PIK3CA mutated [H1047R]) were used for the study. We tested real-time proliferation, 3D-ON TOP colony formation, cell cycle inhibition, changes in mitochondrial membrane potential, and apoptosis following drug treatment as a single-agent (Ribociclib [R]/Trastuzumab [T]) or combination (R+T). Basal-level mRNA transcripts for CDK4 and CCND1 and changes in Ki67 following treatment were quantified with RT-qPCR. Cyclin D expression was evaluated in HER2+ tissue microarrays (TMA) by immunohistochemistry. The mechanistic evaluation of the critical downstream signaling nodes was performed by Western blot. Results: Basal-level mRNA transcript expression for CDK4 and CCND1 were substantially higher (relative to GAPDH) in BT474 and MDA-MB453 whereas, moderate-low expression was obtained in SKBR3. Ki67 transcriptional level was attenuated with R, and further attenuation was observed with dual agent treatment except for SKBR3, where a similar trend was conserved but of reduced intensity. Immunohistochemistry showed substantial cyclin D expression in HER2+ TMA signifying opportunities for CDK4/6 inhibitors. BT474 and MDA-MB453 had similar anti-proliferative responses to the combinatorial treatment, whereas SKBR3 showed resistance to growth inhibition. Similar to real-time proliferation, 3D-ON TOP colony formation showed a reduction in proliferative activities with the combination. The cytostatic response was primarily induced by R and did not differ significantly from the combination of treatment. BT474 and MDA-MB453 had >90% G1 phase arrest, while SKBR3 had >70% G1 phase arrest. Changes in the mitochondrial membrane potential and apoptosis were pronounced with the combination in BT474 and MDA-MB453, whereas SKBR3 did not show any significant response. Western blot showed a reduction in Rb phosphorylation (pRb Ser 780 & Ser 807/811) in all cell lines with R treatment, and further attenuation was observed with combinatorial treatment. Changes in the phospho-Akt were more evident with T and R+T combination in BT474 and MDA-MB453 over HER2-amplified/HR-negative SKBR3 cells. Conclusions: The R+T combination counteracted the proliferative signaling in the HR-positive conditions and sensitized neoplastic cells to elicit an enhanced anti-tumorigenic response irrespective of PIK3CA hotspot mutation. Citation Format: Nischal Koirala, Jennifer Aske, Xiaoqian Lin, Nandini Dey, Pradip De. Scope of cell cycle inhibition in HER2+ breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1775.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 1775
Open AccessAbstract 1775: Scope of cell cycle inhibition in HER2+ breast cancer
Background: Proliferative signaling of the HER2- and ER-pathways converge and propagate via cyclin D and CDK4/6, leading to uncontrolled cell cycle progression and resistance to anti- HER2- and ER-targeted therapies. Purpose: We hypothesize that co-targeting HER2 and CDK4/6 will counter the uncontrolled cell cycle progression, initiate cell cycle arrest, and induce apoptosis in Rb-proficient HER2-amplified breast cancer (BC) cells. Methods: HER2+ BC cell lines (Rb-WT): BT474 (HR-positive), SKBR3 (HR-negative), and MDA-MB453 (HR-negative, PIK3CA mutated [H1047R]) were used for the study. We tested real-time proliferation, 3D-ON TOP colony formation, cell cycle inhibition, changes in mitochondrial membrane potential, and apoptosis following drug treatment as a single-agent (Ribociclib [R]/Trastuzumab [T]) or combination (R+T). Basal-level mRNA transcripts for CDK4 and CCND1 and changes in Ki67 following treatment were quantified with RT-qPCR. Cyclin D expression was evaluated in HER2+ tissue microarrays (TMA) by immunohistochemistry. The mechanistic evaluation of the critical downstream signaling nodes was performed by Western blot. Results: Basal-level mRNA transcript expression for CDK4 and CCND1 were substantially higher (relative to GAPDH) in BT474 and MDA-MB453 whereas, moderate-low expression was obtained in SKBR3. Ki67 transcriptional level was attenuated with R, and further attenuation was observed with dual agent treatment except for SKBR3, where a similar trend was conserved but of reduced intensity. Immunohistochemistry showed substantial cyclin D expression in HER2+ TMA signifying opportunities for CDK4/6 inhibitors. BT474 and MDA-MB453 had similar anti-proliferative responses to the combinatorial treatment, whereas SKBR3 showed resistance to growth inhibition. Similar to real-time proliferation, 3D-ON TOP colony formation showed a reduction in proliferative activities with the combination. The cytostatic response was primarily induced by R and did not differ significantly from the combination of treatment. BT474 and MDA-MB453 had >90% G1 phase arrest, while SKBR3 had >70% G1 phase arrest. Changes in the mitochondrial membrane potential and apoptosis were pronounced with the combination in BT474 and MDA-MB453, whereas SKBR3 did not show any significant response. Western blot showed a reduction in Rb phosphorylation (pRb Ser 780 & Ser 807/811) in all cell lines with R treatment, and further attenuation was observed with combinatorial treatment. Changes in the phospho-Akt were more evident with T and R+T combination in BT474 and MDA-MB453 over HER2-amplified/HR-negative SKBR3 cells. Conclusions: The R+T combination counteracted the proliferative signaling in the HR-positive conditions and sensitized neoplastic cells to elicit an enhanced anti-tumorigenic response irrespective of PIK3CA hotspot mutation. Citation Format: Nischal Koirala, Jennifer Aske, Xiaoqian Lin, Nandini Dey, Pradip De. Scope of cell cycle inhibition in HER2+ breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1775.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 269
Abstract 269: PD-L1 dominated tumor-CAF-immune cell crosstalk of stromal microenvironment: Endometrial tumor vs. tumor-adjacent normal
Background: In endometrial cancers (EC), the mechanistic contribution of PD-L1/L2 and PD-1 signaling of host’s stromal microenvironment (SME) [cancer-associated fibroblast (CAF) and immune cells] in relation to the tumor (T) cells is elusive. Aim: To understand the tumor-stroma-immune crosstalk in EC, we studied the compartmental pattern of PD-L1, PD-L2, and PD-1 expression in EC tissues and their matched CAFs from both T and tumor-adjacent normal (N) tissues. Method: Over 116 surgically resected T and N tissues were obtained from consented patients with EC at the Avera Cancer Institute (March ‘16 and September ’21). IHC expression was performed in T, N-epithelium, SME (mesenchyme) in the T and N tissues. The staining intensity and distribution pattern were evaluated by a pathologist using a standard scoring system (1% cut-off value). Since fibroblasts are the most abundant cells of SME, the PD-L1 was parallelly evaluated in the multiple passages of cultured T and N derived CAFs by the qRT-PCR, flow-cytometry, and ICC. Result: The expression of 3 immune checkpoint proteins in the epithelial and mesenchyme of N was limited to only rare and focal positivity for PD-L1. The epithelial compartments of the T tissue, in contrast, had 70% positivity for PD-L1, which was independent of differentiation status, presence of TILs, or lymphovascular invasion. PD-L1 positivity was 90% of the SME of tested samples, identified predominantly in the (1) immune component, including macrophages and lymphocytes, and (2) EpCAM-/SMA+/FAP+/S100A4+ CAFs. Both PD-L1 and PD-L2 were identified by flow, ICC, and qRT-PCR in NCAF and TCAF. The overall expression of PD-L2 was found to be qualitatively and quantitatively lesser than that of PD-L1, primarily contributed by SME/stromal macrophages and lymphocytes. PD-1 expression was restricted to the SME/stromal immune components, predominantly lymphocytes. The expression for PD-L1 and PD-L2 mRNA was higher in TCAF than NCAF in successive passages, which ICC and flow cytometry confirmed. Summary: The expression of immune checkpoint proteins, PD-L1, and PD-L2, are primarily tumor-driven and associated with the endometrioid (invasive) and serous adenocarcinomas of grades II and above with myometrial invasion. The expression of PD-L1 and PD-L2 are distributed in both tumor and SME/stromal components, while PD-1 expression is exclusively SME/stromal. Citation Format: Xiaoqian Lin, Jennifer Aske, Adam Dale, Nischal Koirala, Ethan Thompson, Mary Fagerness, Natasha Flier, Paige Davies, Stacy Kehoe, Cheryl Ageton, Kris Gaster, Luis Rojas Espaillat, David Starks, Raed Sulaiman, Pradip De, Nandini Dey. PD-L1 dominated tumor-CAF-immune cell crosstalk of stromal microenvironment: Endometrial tumor vs. tumor-adjacent normal [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 269.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 269
Open AccessAbstract 269: PD-L1 dominated tumor-CAF-immune cell crosstalk of stromal microenvironment: Endometrial tumor vs. tumor-adjacent normal
Background: In endometrial cancers (EC), the mechanistic contribution of PD-L1/L2 and PD-1 signaling of host’s stromal microenvironment (SME) [cancer-associated fibroblast (CAF) and immune cells] in relation to the tumor (T) cells is elusive. Aim: To understand the tumor-stroma-immune crosstalk in EC, we studied the compartmental pattern of PD-L1, PD-L2, and PD-1 expression in EC tissues and their matched CAFs from both T and tumor-adjacent normal (N) tissues. Method: Over 116 surgically resected T and N tissues were obtained from consented patients with EC at the Avera Cancer Institute (March ‘16 and September ’21). IHC expression was performed in T, N-epithelium, SME (mesenchyme) in the T and N tissues. The staining intensity and distribution pattern were evaluated by a pathologist using a standard scoring system (1% cut-off value). Since fibroblasts are the most abundant cells of SME, the PD-L1 was parallelly evaluated in the multiple passages of cultured T and N derived CAFs by the qRT-PCR, flow-cytometry, and ICC. Result: The expression of 3 immune checkpoint proteins in the epithelial and mesenchyme of N was limited to only rare and focal positivity for PD-L1. The epithelial compartments of the T tissue, in contrast, had 70% positivity for PD-L1, which was independent of differentiation status, presence of TILs, or lymphovascular invasion. PD-L1 positivity was 90% of the SME of tested samples, identified predominantly in the (1) immune component, including macrophages and lymphocytes, and (2) EpCAM-/SMA+/FAP+/S100A4+ CAFs. Both PD-L1 and PD-L2 were identified by flow, ICC, and qRT-PCR in NCAF and TCAF. The overall expression of PD-L2 was found to be qualitatively and quantitatively lesser than that of PD-L1, primarily contributed by SME/stromal macrophages and lymphocytes. PD-1 expression was restricted to the SME/stromal immune components, predominantly lymphocytes. The expression for PD-L1 and PD-L2 mRNA was higher in TCAF than NCAF in successive passages, which ICC and flow cytometry confirmed. Summary: The expression of immune checkpoint proteins, PD-L1, and PD-L2, are primarily tumor-driven and associated with the endometrioid (invasive) and serous adenocarcinomas of grades II and above with myometrial invasion. The expression of PD-L1 and PD-L2 are distributed in both tumor and SME/stromal components, while PD-1 expression is exclusively SME/stromal. Citation Format: Xiaoqian Lin, Jennifer Aske, Adam Dale, Nischal Koirala, Ethan Thompson, Mary Fagerness, Natasha Flier, Paige Davies, Stacy Kehoe, Cheryl Ageton, Kris Gaster, Luis Rojas Espaillat, David Starks, Raed Sulaiman, Pradip De, Nandini Dey. PD-L1 dominated tumor-CAF-immune cell crosstalk of stromal microenvironment: Endometrial tumor vs. tumor-adjacent normal [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 269.
- Open Access
- 26 September 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (10) , 1771
Mathematical Models for Blood Flow Quantification in Dialysis Access Using Angiography: A Comparative Study
Blood flow rate in dialysis (vascular) access is the key parameter to examine patency and to evaluate the outcomes of various endovascular interve7ntions. While angiography is extensively used for dialysis access–salvage procedures, to date, there is no image-based blood flow measurement application commercially available in the angiography suite. We aim to calculate the blood flow rate in the dialysis access based on cine-angiographic and fluoroscopic image sequences. In this study, we discuss image-based methods to quantify access blood flow in a flow phantom model. Digital subtraction angiography (DSA) and fluoroscopy were used to acquire images at various sampling rates (DSA—3 and 6 frames/s, fluoroscopy—4 and 10 pulses/s). Flow rates were computed based on two bolus tracking algorithms, peak-to-peak and cross-correlation, and modeled with three curve-fitting functions, gamma variate, lagged normal, and polynomial, to correct errors with transit time measurement. Dye propagation distance and the cross-sectional area were calculated by analyzing the contrast enhancement in the vessel. The calculated flow rates were correlated versus an in-line flow sensor measurement. The cross-correlation algorithm with gamma-variate curve fitting had the best accuracy and least variability in both imaging modes. The absolute percent error (mean ± SEM) of flow quantification in the DSA mode at 6 frames/s was 21.4 ± 1.9%, and in the fluoroscopic mode at 10 pulses/s was 37.4 ± 3.6%. The radiation dose varied linearly with the sampling rate in both imaging modes and was substantially low to invoke any tissue reactions or stochastic effects. The cross-correlation algorithm and gamma-variate curve fitting for DSA acquisition at 6 frames/s had the best correlation with the flow sensor measurements. These findings will be helpful to develop a software-based vascular access flow measurement tool for the angiography suite and to optimize the imaging protocol amenable for computational flow applications.
- 26 September 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (10) , 1771
Open AccessMathematical Models for Blood Flow Quantification in Dialysis Access Using Angiography: A Comparative Study
Blood flow rate in dialysis (vascular) access is the key parameter to examine patency and to evaluate the outcomes of various endovascular interve7ntions. While angiography is extensively used for dialysis access–salvage procedures, to date, there is no image-based blood flow measurement application commercially available in the angiography suite. We aim to calculate the blood flow rate in the dialysis access based on cine-angiographic and fluoroscopic image sequences. In this study, we discuss image-based methods to quantify access blood flow in a flow phantom model. Digital subtraction angiography (DSA) and fluoroscopy were used to acquire images at various sampling rates (DSA—3 and 6 frames/s, fluoroscopy—4 and 10 pulses/s). Flow rates were computed based on two bolus tracking algorithms, peak-to-peak and cross-correlation, and modeled with three curve-fitting functions, gamma variate, lagged normal, and polynomial, to correct errors with transit time measurement. Dye propagation distance and the cross-sectional area were calculated by analyzing the contrast enhancement in the vessel. The calculated flow rates were correlated versus an in-line flow sensor measurement. The cross-correlation algorithm with gamma-variate curve fitting had the best accuracy and least variability in both imaging modes. The absolute percent error (mean ± SEM) of flow quantification in the DSA mode at 6 frames/s was 21.4 ± 1.9%, and in the fluoroscopic mode at 10 pulses/s was 37.4 ± 3.6%. The radiation dose varied linearly with the sampling rate in both imaging modes and was substantially low to invoke any tissue reactions or stochastic effects. The cross-correlation algorithm and gamma-variate curve fitting for DSA acquisition at 6 frames/s had the best correlation with the flow sensor measurements. These findings will be helpful to develop a software-based vascular access flow measurement tool for the angiography suite and to optimize the imaging protocol amenable for computational flow applications.
- Open Access
- 30 January 2021
- Published by Igor Sikorsky Kyiv Polytechnic Institute in Известия высших учебных заведений. Радиоэлектроника
- Vol. 64 (1) , 31-42
Сверхширокополосный малошумящий усилитель на основе активной катушки индуктивности с подавлением помех беспроводной локальной сети
В статье предложен сверхширокополосный малошумящий усилитель (МШУ) в диапазоне частот 3,1–10,6 ГГц на основе топологии активной катушки индуктивности. МШУ разработан для обеспечения постоянного коэффициента усиления и подавления помех от беспроводной локальной сети в диапазоне частот 5–6 ГГц. В работе представлена активная катушка индуктивности на основе топологии резистора обратной связи, интегрированная с МШУ. Использование активной катушки индуктивности вместо стандартной спиральной КМОП катушки обеспечивает выигрыш по площади, добротности и значению индуктивности. Активная катушка индуктивности обеспечивает относительно равномерное значение индуктивности на частотах 5–6 ГГц и используется для работы режекторного фильтра на кристалле, с максимальным затуханием 45 дБ на центральной частоте ~5,6 ГГц. МШУ спроектирован и работает по стандартной КМОП-технологии 0,18 мкм. Спроектированный МШУ обеспечивает усиление 20 дБ и коэффициент шума менее 3,7 дБ в различных диапазонах частот. Обратные потери на входе (S11) и выходе (S22) составляют менее –10 и –12 дБ, соответственно, в указанном диапазоне частотного спектра, при этом усилитель занимает площадь кристалла 0,54 мкм2. Разработанный МШУ имеет высокий равномерный коэффициент усиления, высокое подавление помех, минимальные значения обратных потерь и низкий коэффициент шума в диапазоне 3,1–10,6 ГГц. Данный МШУ рекомендуется к использованию во входных каскадах различных устройств.
- 30 January 2021
- Published by Igor Sikorsky Kyiv Polytechnic Institute in Известия высших учебных заведений. Радиоэлектроника
- Vol. 64 (1) , 31-42
Open AccessСверхширокополосный малошумящий усилитель на основе активной катушки индуктивности с подавлением помех беспроводной локальной сети
В статье предложен сверхширокополосный малошумящий усилитель (МШУ) в диапазоне частот 3,1–10,6 ГГц на основе топологии активной катушки индуктивности. МШУ разработан для обеспечения постоянного коэффициента усиления и подавления помех от беспроводной локальной сети в диапазоне частот 5–6 ГГц. В работе представлена активная катушка индуктивности на основе топологии резистора обратной связи, интегрированная с МШУ. Использование активной катушки индуктивности вместо стандартной спиральной КМОП катушки обеспечивает выигрыш по площади, добротности и значению индуктивности. Активная катушка индуктивности обеспечивает относительно равномерное значение индуктивности на частотах 5–6 ГГц и используется для работы режекторного фильтра на кристалле, с максимальным затуханием 45 дБ на центральной частоте ~5,6 ГГц. МШУ спроектирован и работает по стандартной КМОП-технологии 0,18 мкм. Спроектированный МШУ обеспечивает усиление 20 дБ и коэффициент шума менее 3,7 дБ в различных диапазонах частот. Обратные потери на входе (S11) и выходе (S22) составляют менее –10 и –12 дБ, соответственно, в указанном диапазоне частотного спектра, при этом усилитель занимает площадь кристалла 0,54 мкм2. Разработанный МШУ имеет высокий равномерный коэффициент усиления, высокое подавление помех, минимальные значения обратных потерь и низкий коэффициент шума в диапазоне 3,1–10,6 ГГц. Данный МШУ рекомендуется к использованию во входных каскадах различных устройств.
- 1 January 2021
- Published by Allerton Press in Radioelectronics and Communications Systems
- Vol. 64 (1) , 26-35
Active Inductor-Based Ultra-Wideband Low Noise Amplifier for Rejection of Wireless LAN Interference
This paper presents a low noise amplifier (LNA) for the ultra-wideband (UWB) application in the range 3.1–10.6 GHz based on active inductor topology.
- 1 January 2021
- Published by Allerton Press in Radioelectronics and Communications Systems
- Vol. 64 (1) , 26-35
Active Inductor-Based Ultra-Wideband Low Noise Amplifier for Rejection of Wireless LAN Interference
This paper presents a low noise amplifier (LNA) for the ultra-wideband (UWB) application in the range 3.1–10.6 GHz based on active inductor topology.
- 4 August 2019
- Published by Springer Nature in Skeletal Radiology
- Vol. 49 (3) , 375-382
Percutaneous reinforced osteoplasty for long bone metastases: a feasibility study
Objective While percutaneous osteoplasty is common for the treatment of vertebral fractures, low strength of fixation remains a major challenge for use in metastatic weight-bearing bones. With stent, wire, and cement augmentation, this study explores the feasibility of percutaneous reinforced osteoplasty for use in correcting long bone fractures. Materials and methods Fifteen explanted swine femora were randomly assigned into three groups. Group 1 (n = 5) was native (intact) bones without any intervention (control), group 2 (n = 5) received cementoplasty, and group 3 (n = 5) received stent and wire scaffolding (“rebar”) in addition to cementoplasty. All treatment procedures were performed under fluoroscopic guidance. Mechanical strength of fracture fixation was quantified by peak load to failure, stiffness, work done to fracture, and fatigue testing with four-point bend test. Results Percutaneous osteoplasty with or without reinforcement was successfully achieved in all specimens. The respective peak load at failure, flexural stiffness, and work done to fracture (mean ± SEM) for group 1 was 2245 ± 168 N, 14.77 ± 1.3 Nm/degree, and 4854 ± 541 Nmm; group 2 was 468 ± 81 N, 3.9 ± 0.5 Nm/degree, and 401 ± 56 Nmm; and group 3 was 594 ± 90 N, 4.42 ± 0.4 Nm/degree, and 522 ± 54 Nmm. The mean cyclic displacement for groups 1, 2, and 3 were 0.15, 0.58, and 0.48 mm, respectively, at 220–240 N loading. Conclusions While percutaneous reinforced osteoplasty with stent, wire, and cement augmentation resulted in improved mechanical strength in restored bones, it did not differ significantly from specimens that underwent exclusive cementoplasty. With the improvement of fracture strength, the concept may be applicable for prevention or treatment of pathological fractures.
- 4 August 2019
- Published by Springer Nature in Skeletal Radiology
- Vol. 49 (3) , 375-382
Percutaneous reinforced osteoplasty for long bone metastases: a feasibility study
Objective While percutaneous osteoplasty is common for the treatment of vertebral fractures, low strength of fixation remains a major challenge for use in metastatic weight-bearing bones. With stent, wire, and cement augmentation, this study explores the feasibility of percutaneous reinforced osteoplasty for use in correcting long bone fractures. Materials and methods Fifteen explanted swine femora were randomly assigned into three groups. Group 1 (n = 5) was native (intact) bones without any intervention (control), group 2 (n = 5) received cementoplasty, and group 3 (n = 5) received stent and wire scaffolding (“rebar”) in addition to cementoplasty. All treatment procedures were performed under fluoroscopic guidance. Mechanical strength of fracture fixation was quantified by peak load to failure, stiffness, work done to fracture, and fatigue testing with four-point bend test. Results Percutaneous osteoplasty with or without reinforcement was successfully achieved in all specimens. The respective peak load at failure, flexural stiffness, and work done to fracture (mean ± SEM) for group 1 was 2245 ± 168 N, 14.77 ± 1.3 Nm/degree, and 4854 ± 541 Nmm; group 2 was 468 ± 81 N, 3.9 ± 0.5 Nm/degree, and 401 ± 56 Nmm; and group 3 was 594 ± 90 N, 4.42 ± 0.4 Nm/degree, and 522 ± 54 Nmm. The mean cyclic displacement for groups 1, 2, and 3 were 0.15, 0.58, and 0.48 mm, respectively, at 220–240 N loading. Conclusions While percutaneous reinforced osteoplasty with stent, wire, and cement augmentation resulted in improved mechanical strength in restored bones, it did not differ significantly from specimens that underwent exclusive cementoplasty. With the improvement of fracture strength, the concept may be applicable for prevention or treatment of pathological fractures.
- 23 July 2019
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 107 (11) , 2522-2535
Folic acid conjugated polymeric drug delivery vehicle for targeted cancer detection in hepatocellular carcinoma
Targeted therapies provide increased efficiency for the detection and treatment of cancer with reduced side effects. Folate receptor (alpha subunit) is overexpressed in multiple tumors including liver cancer. In this study, we evaluated the specificity and toxicity of a folic acid‐containing drug delivery vehicle (DDV) in a hepatocellular carcinoma (HCC) model. The DDV was prepared with two units each of folic acid (FA) and fluorescein isothiocyanate (FITC) molecules and conjugated to a central poly (ethylene glycol) (PEG) core via a modified chemo‐enzymatic synthetic process. Rat hepatoma (N1S1) and human monocytic (U937) cell lines were used for cell culture‐based assays and tested for DDV uptake and toxicity. Folate receptor expressions in liver tissues and cell lines were verified using standard immunohistochemistry techniques. Rat HCC model was used for in vivo assessment. The DDV was injected via intra‐arterial or intravenous methods and imaged with IVIS spectrum in vivo imaging system. Strong signals of FITC in the liver tumor region correlated to targeted DDV uptake. The use of PEG enhanced water‐solubility and provided flexibility for the interaction of FA ligands with multiple cell surface folate receptors that resulted in increased specific uptake. Our study suggested that PEG incorporation and folate targeting via intra‐arterial approach is an efficient strategy for targeted delivery in HCC therapy.
- 23 July 2019
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 107 (11) , 2522-2535
Folic acid conjugated polymeric drug delivery vehicle for targeted cancer detection in hepatocellular carcinoma
Targeted therapies provide increased efficiency for the detection and treatment of cancer with reduced side effects. Folate receptor (alpha subunit) is overexpressed in multiple tumors including liver cancer. In this study, we evaluated the specificity and toxicity of a folic acid‐containing drug delivery vehicle (DDV) in a hepatocellular carcinoma (HCC) model. The DDV was prepared with two units each of folic acid (FA) and fluorescein isothiocyanate (FITC) molecules and conjugated to a central poly (ethylene glycol) (PEG) core via a modified chemo‐enzymatic synthetic process. Rat hepatoma (N1S1) and human monocytic (U937) cell lines were used for cell culture‐based assays and tested for DDV uptake and toxicity. Folate receptor expressions in liver tissues and cell lines were verified using standard immunohistochemistry techniques. Rat HCC model was used for in vivo assessment. The DDV was injected via intra‐arterial or intravenous methods and imaged with IVIS spectrum in vivo imaging system. Strong signals of FITC in the liver tumor region correlated to targeted DDV uptake. The use of PEG enhanced water‐solubility and provided flexibility for the interaction of FA ligands with multiple cell surface folate receptors that resulted in increased specific uptake. Our study suggested that PEG incorporation and folate targeting via intra‐arterial approach is an efficient strategy for targeted delivery in HCC therapy.